The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections
Abstract
Treatments for invasive fungal infections remain unsatisfactory. We evaluated the efficacy, tolerability, and safety of voriconazole as salvage treatment for 273 patients with refractory and intolerant-to-treatment fungal infections and as primary treatment for 28 patients with infections for which there is no approved therapy. Voriconazole was associated with satisfactory global responses in 50% of the overall cohort; specifically, successful outcomes were observed in 47% of patients whose infections failed to respond to previous antifungal therapy and in 68% of patients whose infections have no approved antifungal therapy. In this population at high risk for treatment failure, the efficacy rates for voriconazole were 43.7% for aspergillosis, 57.5% for candidiasis, 38.9% for cryptococcosis, 45.5% for fusariosis, and 30% for scedosporiosis. Voriconazole was well tolerated, and treatment-related discontinuations of therapy or dose reductions occurred for <10% of patients. Voriconazole is an effective and well-tolerated treatment for refractory or less-common invasive fungal infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Self-citationEpidemiology and Outcome of Mould Infections in Hematopoietic Stem Cell Transplant Recipients
Marr, K. A., Carter, R. A., Crippa, F., Wald, A., & Corey, L. (2002) · Clinical Infectious Diseases · doi:10.1086/339202 · Cited by 1,448
Self-citationAspergillosis Case-Fatality Rate: Systematic Review of the Literature
Lin, S.-J., Schranz, J., & Teutsch, S. M. (2001) · Clinical Infectious Diseases · doi:10.1086/318483 · Cited by 1,409
Modelling Survival Data in Medical Research
Collett, D. (1994) · Springer eBooks · doi:10.1007/978-1-4899-3115-3 · Cited by 1,065
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039
Walsh, T. J., Pappas, P., Winston, D. J., Lazarus, H. M., Petersen, F., Raffalli, J., Yanovich, S., Stiff, P., Greenberg, R., Donowitz, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejm200201243460403 · Cited by 979
Self-citationAntifungal and Surgical Treatment of Invasive Aspergillosis: Review of 2,121 Published Cases
Denning, D. W., & Stevens, D. A. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.6.1147 · Cited by 899
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
Denning, D. W., Ribaud, P., Milpied, N., Caillot, D., Herbrecht, R., Thiel, E., Haas, A., Ruhnke, M., & Lode, H. (2002) · Clinical Infectious Diseases · doi:10.1086/324620 · Cited by 844 · cited 3×
“In refractory aspergillosis, the overall success rate for ABLC was 42% (55 of 130 patients), compared with a rate of 44% (62 of 142) for voriconazole in this study, and compared with a previous report of voriconazole salvage therapy for aspergillosis, which reported success in 21 (38%) of 56 patients [1].”
BackgroundResultInvasive Aspergillosis Disease Spectrum, Treatment Practices, and Outcomes
Patterson, T. F., Kirkpatrick, W. R., White, M., Hiemenz, J. W., WINGARD, J. R., DUPONT, B., RINALDI, M. G., STEVENS, D. A., & Graybill, J. R. (2000) · Medicine · doi:10.1097/00005792-200007000-00006 · Cited by 791
Self-citationWalsh, T. J., Hiemenz, J. W., Seibel, N. L., Perfect, J. R., Horwith, G., Lee, L., Silber, J. L., DiNubile, M. J., Reboli, A., Bow, E., et al. (1998) · Clinical Infectious Diseases · doi:10.1086/516353 · Cited by 629
Self-citation
Cited by
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
Self-citationWalsh, T. J., Anaissie, E. J., Denning, D. W., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Segal, B. H., Steinbach, W. J., Stevens, D. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/525258 · Cited by 2,706
Self-citationPerfect, J. R., Dismukes, W. E., Dromer, F., Goldman, D. L., Graybill, J. R., Hamill, R. J., Harrison, T. S., Larsen, R. A., Lortholary, O., Nguyen, M.-H., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649858 · Cited by 2,660
Self-citationUllmann, A. J., Aguado, J. M., Arikan-Akdagli, S., Denning, D. W., Groll, A. H., Lagrou, K., Lass-Flörl, C., Lewis, R. E., Munoz, P., Verweij, P. E., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.01.002 · Cited by 1,556
Novel perspectives on mucormycosis: pathophysiology, presentation, and management
Spellberg, B., Edwards, J., & Ibrahim, A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.3.556-569.2005 · Cited by 1,537
Cornely, O. A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B. J., Lortholary, O., Meersseman, W., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12039 · Cited by 1,217
Histoplasmosis: a Clinical and Laboratory Update
Kauffman, C. A. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00027-06 · Cited by 1,200
Fusarium Infections in Immunocompromised Patients
Nucci, M., & Anaissie, E. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00014-07 · Cited by 983
Epidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
Pascual, A., Calandra, T., Bolay, S., Buclin, T., Bille, J., & Marchetti, O. (2008) · Clinical Infectious Diseases · doi:10.1086/524669 · Cited by 887
Maziarz, E. K., & Perfect, J. R. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.006 · Cited by 698
Self-citationPfaller, M. A., & Diekema, D. J. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.10.4419-4431.2004 · Cited by 694
Kontoyiannis, D. P., Lionakis, M. S., Lewis, R. E., Chamilos, G., Healy, M., Perego, C., Safdar, A., Kantarjian, H., Champlin, R., Walsh, T. J., et al. (2005) · The Journal of Infectious Diseases · doi:10.1086/428780 · Cited by 674
Self-citationMaertens, J., Raad, I., Petrikkos, G., Boogaerts, M., Selleslag, D., Petersen, F. B., Sable, C. A., Kartsonis, N. A., Ngai, A., Taylor, A., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/423381 · Cited by 658
Self-citationLimper, A. H., Knox, K. S., Sarosi, G. A., Ampel, N. M., Bennett, J. E., Catanzaro, A., Davies, S. F., Dismukes, W. E., Hage, C. A., Marr, K. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2008-740st · Cited by 612
Self-citationPosaconazole as Salvage Therapy for Zygomycosis
Greenberg, R. N., Mullane, K., van Burik, J.-A. H., Raad, I., Abzug, M. J., Anstead, G., Herbrecht, R., Langston, A., Marr, K. A., Schiller, G., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.1.126-133.2006 · Cited by 555
Self-citationKullberg, B., Sobel, J., Ruhnke, M., Pappas, P., Viscoli, C., Rex, J., Cleary, J., Rubinstein, E., Church, L., Brown, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67490-9 · Cited by 521
Self-citationTortorano, A. M., Richardson, M., Roilides, E., van Diepeningen, A., Caira, M., Munoz, P., Johnson, E., Meletiadis, J., Pana, Z.-D., Lackner, M., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12465 · Cited by 523
Self-citationDetection of circulating galactomannan for the diagnosis and management of invasive aspergillosis
Mennink-Kersten, M. A., Donnelly, J. P., & Verweij, P. E. (2004) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(04)01045-x · Cited by 482
O'Donnell, K., Sutton, D. A., Fothergill, A., McCarthy, D., Rinaldi, M. G., Brandt, M. E., Zhang, N., & Geiser, D. M. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.02371-07 · Cited by 480
Hoenigl, M., Salmanton-García, J., Walsh, T. J., Nucci, M., Neoh, C. F., Jenks, J. D., Lackner, M., Sprute, R., Al-Hatmi, A. M. S., Bassetti, M., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30784-2 · Cited by 470
Self-citationSegal, B. H., Herbrecht, R., Stevens, D. A., Ostrosky‐Zeichner, L., Sobel, J., Viscoli, C., Walsh, T. J., Maertens, J., Patterson, T. F., Perfect, J. R., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/590566 · Cited by 468
Self-citationInvasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease
Bulpa, P., Dive, A., & Sibille, Y. (2007) · European Respiratory Journal · doi:10.1183/09031936.00062206 · Cited by 466
Invasive Fungal Pathogens: Current Epidemiological Trends
Pfaller, M. A., Pappas, P. G., & Wingard, J. R. (2006) · Clinical Infectious Diseases · doi:10.1086/504490 · Cited by 448
Nucci, M., & Marr, K. A. (2005) · Clinical Infectious Diseases · doi:10.1086/432060 · Cited by 435
Self-citationImpact of Melanin on Microbial Virulence and Clinical Resistance to Antimicrobial Compounds
Nosanchuk, J. D., & Casadevall, A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00545-06 · Cited by 408
Groll, A. H., Castagnola, E., Cesaro, S., Dalle, J.-H., Engelhard, D., Hope, W., Roilides, E., Styczynski, J., Warris, A., & Lehrnbecher, T. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70017-8 · Cited by 407
Primary Central Nervous System Phaeohyphomycosis: A Review of 101 Cases
Revankar, S. G., Sutton, D. A., & Rinaldi, M. G. (2004) · Clinical Infectious Diseases · doi:10.1086/380635 · Cited by 405
Breakthrough Fungal Infections in Stem Cell Transplant Recipients Receiving Voriconazole
Imhof, A., Balajee, S. A., Fredricks, D. N., Englund, J. A., & Marr, K. A. (2004) · Clinical Infectious Diseases · doi:10.1086/423274 · Cited by 402
Self-citationImproved outcome in central nervous system aspergillosis, using voriconazole treatment
Schwartz, S. (2005) · Blood · doi:10.1182/blood-2005-02-0733 · Cited by 391
Song, C. K., Balakrishnan, P., Shim, C.-K., Chung, S.-J., Chong, S., & Kim, D.-D. (2012) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2011.12.004 · Cited by 380
Chayakulkeeree, M., & Perfect, J. R. (2006) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2006.07.001 · Cited by 378
Self-citationCurrent Concepts in Antifungal Pharmacology
Lewis, R. E. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2011.0247 · Cited by 377
Diekema, D. J., Messer, S. A., Hollis, R. J., Jones, R. N., & Pfaller, M. A. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.8.3623-3626.2003 · Cited by 371
Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Bijie, H., Dzierzanowska, D., Klimko, N. N., Letscher-Bru, V., Lisalova, M., Muehlethaler, K., et al. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.01747-08 · Cited by 370
Prevention and Treatment of Cancer-Related Infections
Baden, L. R., Bensinger, W., Angarone, M., Casper, C., Dubberke, E. R., Freifeld, A. G., Garzon, R., Greene, J. N., Greer, J. P., Ito, J. I., et al. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0146 · Cited by 368
Self-citationBicanic, T., & Harrison, T. S. (2004) · British Medical Bulletin · doi:10.1093/bmb/ldh043 · Cited by 361
Nett, J. E., & Andes, D. R. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.012 · Cited by 351
Husain, S., Alexander, B. D., Munoz, P., Avery, R. K., Houston, S., Pruett, T., Jacobs, R., Dominguez, E. A., Tollemar, J. G., Baumgarten, K., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/375822 · Cited by 337
Fusarium Infection in Hematopoietic Stem Cell Transplant Recipients
Nucci, M., Marr, K. A., Queiroz-Telles, F., Martins, C. A., Trabasso, P., Costa, S., Voltarelli, J. C., Colombo, A. L., Imhof, A., Pasquini, R., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/383319 · Cited by 333
Self-citationChang, C. C., Harrison, T. S., Bicanic, T. A., Chayakulkeeree, M., Sorrell, T. C., Warris, A., Hagen, F., Spec, A., Oladele, R., Govender, N. P., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00731-4 · Cited by 326
Self-citationEmerging fungal infections in immunocompromised patients
Low, C.-Y., & Rotstein, C. (2011) · F1000 Medicine Reports · doi:10.3410/m3-14 · Cited by 309
Newer Systemic Antifungal Agents: Pharmacokinetics, Safety and Efficacy
Boucher, H. W., Groll, A. H., Chiou, C. C., & Walsh, T. J. (2004) · Drugs · doi:10.2165/00003495-200464180-00001 · Cited by 305
Self-citationRaad, I. I., Hachem, R. Y., Herbrecht, R., Graybill, J. R., Hare, R., Corcoran, G., & Kontoyiannis, D. P. (2006) · Clinical Infectious Diseases · doi:10.1086/503425 · Cited by 302
Scedosporium apiospermum: changing clinical spectrum of a therapy-refractory opportunist*
Guarro, J., Kantarcioglu, A. S., Horré, R., Luis Rodriguez-Tudela, J., Cuenca Estrella, M., Berenguer, J., & Sybren De Hoog, G. (2006) · Medical Mycology · doi:10.1080/13693780600752507 · Cited by 297
Treatment of Scedosporiosis with Voriconazole: Clinical Experience with 107 Patients
Troke, P., Aguirrebengoa, K., Arteaga, C., Ellis, D., Heath, C. H., Lutsar, I., Rovira, M., Nguyen, Q., Slavin, M., & Chen, S. C. A. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01388-07 · Cited by 294
Self-citationInfections Due to Aspergillus terreus: A Multicenter Retrospective Analysis of 83 Cases
Steinbach, W. J., Benjamin, D. K., Kontoyiannis, D. P., Perfect, J. R., Lutsar, I., Marr, K. A., Lionakis, M. S., Torres, H. A., Jafri, H., & Walsh, T. J. (2004) · Clinical Infectious Diseases · doi:10.1086/421950 · Cited by 293
Self-citationPfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Meis, J. F., Gould, I. M., Fu, W., Colombo, A. L., & Rodriguez-Noriega, E. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.00409-07 · Cited by 284
Ullmann, A. J., Cornely, O. A., Burchardt, A., Hachem, R., Kontoyiannis, D. P., Töpelt, K., Courtney, R., Wexler, D., Krishna, G., Martinho, M., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.2.658-666.2006 · Cited by 273
Triazole Antifungal Agents in Invasive Fungal Infections: A Comparative Review
Lass-Flörl, C. (2011) · Drugs · doi:10.2165/11596540-000000000-00000 · Cited by 270
Pfaller, M. A., Diekema, D. J., Rex, J. H., Espinel-Ingroff, A., Johnson, E. M., Andes, D., Chaturvedi, V., Ghannoum, M. A., Odds, F. C., Rinaldi, M. G., et al. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.3.819-826.2006 · Cited by 258
Self-citationAspergillus Section Fumigati : Antifungal Susceptibility Patterns and Sequence-Based Identification
Alcazar-Fuoli, L., Mellado, E., Alastruey-Izquierdo, A., Cuenca-Estrella, M., & Rodriguez-Tudela, J. L. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00942-07 · Cited by 258
Tan, K., Brayshaw, N., Tomaszewski, K., Troke, P., & Wood, N. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005283837 · Cited by 256
Mousset, S., Buchheidt, D., Heinz, W., Ruhnke, M., Cornely, O. A., Egerer, G., Krüger, W., Link, H., Neumann, S., Ostermann, H., et al. (2014) · Annals of Hematology · doi:10.1007/s00277-013-1867-1 · Cited by 255
Azole antifungals: 35 years of invasive fungal infection management
Allen, D., Wilson, D., Drew, R., & Perfect, J. (2015) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2015.1032939 · Cited by 255
Self-citationHIV-associated cryptococcal meningitis
Jarvis, J. N., & Harrison, T. S. (2007) · AIDS · doi:10.1097/qad.0b013e3282a4a64d · Cited by 252
(2003) · PubMed · Cited by 240
Pfaller, M. A., Messer, S. A., Woosley, L. N., Jones, R. N., & Castanheira, M. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.00308-13 · Cited by 237
Ostrosky-Zeichner, L., Kontoyiannis, D., Raffalli, J., Mullane, K. M., Vazquez, J., Anaissie, E. J., Lipton, J., Jacobs, P., Rensburg, J. H. J., Rex, J. H., et al. (2005) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-005-0024-8 · Cited by 189
Cordonnier, C., Rovira, M., Maertens, J., Olavarria, E., Faucher, C., Bilger, K., Pigneux, A., Cornely, O. A., Ullmann, A. J., Bofarull, R. M., et al. (2010) · Haematologica · doi:10.3324/haematol.2009.020073 · Cited by 137
Pfaller, M. A., Andes, D., Arendrup, M. C., Diekema, D. J., Espinel-Ingroff, A., Alexander, B. D., Brown, S. D., Chaturvedi, V., Fowler, C. L., Ghannoum, M. A., et al. (2011) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2011.03.002 · Cited by 130
Self-citationLewis, R. E., Wiederhold, N. P., & Klepser, M. E. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.3.945-951.2005 · Cited by 129
Endemic Mycoses: Blastomycosis, Histoplasmosis, and Sporotrichosis
Kauffman, C. A. (2006) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2006.07.002 · Cited by 113
New generation azole antifungals in clinical investigation
Girmenia, C. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903176407 · Cited by 107
Castanheira, M., Duncanson, F. P., Diekema, D. J., Guarro, J., Jones, R. N., & Pfaller, M. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05414-11 · Cited by 98
Pfaller, M. A., Messer, S. A., Boyken, L., Rice, C., Tendolkar, S., Hollis, R. J., & Diekema, D. J. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.01551-06 · Cited by 77
Clinical efficacy of new antifungal agents
Kauffman, C. A. (2006) · Current Opinion in Microbiology · doi:10.1016/j.mib.2006.08.001 · Cited by 64
Cost of invasive fungal infections in the era of new diagnostics and expanded treatment options
Ashley, E. D., Drew, R., Johnson, M., Danna, R., Dabrowski, D., Walker, V., Prasad, M., Alexander, B., Papadopoulos, G., & Perfect, J. (2012) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.2012.01124 · Cited by 62
Self-citationFungal Infections in Transplant and Oncology Patients
Person, A. K., Kontoyiannis, D. P., & Alexander, B. D. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.11.013 · Cited by 33
New and emerging infectious diseases
Elston, D. M. (2005) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.02.048 · Cited by 18
Metadata
- Authors
- Perfect, J. R., Marr, K. A., Walsh, T. J., Greenberg, R. N., DuPont, B., de la Torre‐Cisneros, J., Just‐Nubling, G., Schlamm, H. T., Lutsar, I., Espinel‐Ingroff, A., & Johnson, E.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-05
- Volume
- 36
- Issue
- 9
- Pages
- 1122-1131
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2087548480
- Cited by
- 680
- References
- 34
- FWCI
- 33.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.